Contents

xi Introduction

Scientific Presentations

1 Chemistry and Manufacture of the Biotechnologically-derived Drugs
Y.-Y. H. Chiu, John L. Gueriguian and Solomon Sobel

23 HPLC and Biotechnological Products
D. H. Calam

29 The Use and Limitations of Reversed Phase HPLC for the Analysis of Recombinant Proteins and their Tryptic Digests
W. S. Hancock, E. Canova-Davis, J. Battersby and R. Chloupek

50 An Evaluation of the Pharmacotoxicity of Biotechnology Products
Alex Jordan

61 Imaging of Human Colorectal Carcinoma with an Indium-Labelled Anti-CEA Monoclonal Antibody
B. Merchant, W. Unger, and S. S. Scheighardt

74 Structural Characterization and Biosynthesis of Carbohydrates in Glycoprotein Hormones
Om P. Bahl

106 Continuous Cell Lines as Substrates for the Production of Biotechnologically-derived Products
John C. Petricciani

122 Clinical Validation of Recombinant DNA Products
John L. Gueriguian and Y.-Y. H. Chiu

Current Regulatory Situation

136 Canada - *David Pope*

138 Federal Republic of Germany - *R. Bass and E. Scheibner*

146 France - *M. D. Campion*

149 Italy - *Duilio Poggiolini*

152 Japan - *Takao Hayakawa*

157 United Kingdom - *Gerald Jones and John Purves*

163 United States of America - *Elaine Esber*

Point of View of the Industry

168 The Point of View from Industry
Michael J. Ross

175 Scientific Basis for Regulations of rDNA Products
An Industrial View
Tony Plane

Thematic Discussions

186 Theme I — Proper Chemical Analysis and Safe Development of Biotechnologically-derived Medical Agents

188 Theme II — Traditional and Modern Pharmaco-toxicological Requirements for Biotechnological Products

191 Theme III — Safety Issues Related to the Use of Eukaryotic, Particularly Mammalian Cell Systems

194 Theme IV - Immunogenicity and the Potential for Untoward Reactions